Skip to main content

FDA Approvals

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approvals, Lung Cancer, Oncology

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Prostate Cancer

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

FDA Approvals, Lung Cancer, Oncology

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

Page 17 of 53
Results 161 - 170 of 527